Adagio Medical Holdings (ADGM) Q1 2025 earnings summary

Executive summary

• Focused on developing and commercializing catheter-based cryoablation technologies for cardiac arrhythmias, with a primary emphasis on ventricular tachycardia (VT).

• Achieved FDA Breakthrough Device Designation for vCLAS Cryoablation System targeting VT, supporting accelerated regulatory review.

• Surpassed 50% enrollment in pivotal FULCRUM-VT study, on track for completion in the second half of 2025.

• Completed a business combination in July 2024, resulting in a new public entity and significant changes to capital structure.

• Implemented a corporate prioritization initiative in February 2025, concentrating resources on the FULCRUM-VT clinical trial and product design optimization.

Financial highlights

• Net loss for Q1 2025 was $7.7 million, or $(0.50) per share, compared to $8.0 million, or $(10.28) per share, in Q1 2024.

• Revenue was nil for Q1 2025, down from $26,000 in Q1 2024, due to a pause in European commercial activity and inventory buyback.

• Cash and cash equivalents were $13.0 million as of March 31, 2025, down from $20.6 million at December 31, 2024.

• Net cash used in operating activities was $7.2 million for Q1 2025, compared to $6.7 million for Q1 2024.

• Research and development expenses increased to $3.7 million from $3.5 million year-over-year.

Outlook and guidance

• Management believes current cash is insufficient to fund operations for the next 12 months, raising substantial doubt about the ability to continue as a going concern.

• Plans to seek additional equity or debt financing, pursue regulatory approvals for U.S. commercialization, and execute cost-cutting measures.

• FULCRUM-VT pivotal study enrollment expected to complete in the second half of 2025, supporting FDA approval efforts.

• Corporate prioritization and resource realignment aimed at accelerating clinical and product development milestones.